On Friday, Galectin Therapeutics Inc (NASDAQ: GALT) was -8.89% drop from the session before settling in for the closing price of $6.3. A 52-week range for GALT has been $0.73 – $6.55.
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -23.89%. When this article was written, the company’s average yearly earnings per share was at 35.53%. With a float of $45.61 million, this company’s outstanding shares have now reached $64.47 million.
Galectin Therapeutics Inc (GALT) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Galectin Therapeutics Inc stocks. The insider ownership of Galectin Therapeutics Inc is 29.26%, while institutional ownership is 15.94%. The most recent insider transaction that took place on Dec 03 ’25, was worth 687,600. In this transaction 10% Owner of this company sold 120,000 shares at a rate of $5.73, taking the stock ownership to the 5,682,207 shares. Before that another transaction happened on Dec 02 ’25, when Company’s 10% Owner sold 30,000 for $5.47, making the entire transaction worth $164,100. This insider now owns 5,802,207 shares in total.
Galectin Therapeutics Inc (GALT) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.19 earnings per share (EPS) during the time that was less than consensus figure (set at -0.16) by -0.03.
According to the Wall Street analysts, stocks earnings will be around 35.53% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.03% during the next five years compared to -23.89% drop over the previous five years of trading.
Galectin Therapeutics Inc (NASDAQ: GALT) Trading Performance Indicators
You can see what Galectin Therapeutics Inc (GALT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 0.09.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.59, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.41 in one year’s time.
Technical Analysis of Galectin Therapeutics Inc (GALT)
The latest stats from [Galectin Therapeutics Inc, GALT] show that its last 5-days average volume of 0.53 million was superior to 0.39 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 55.19%.
During the past 100 days, Galectin Therapeutics Inc’s (GALT) raw stochastic average was set at 77.67%, which indicates a significant increase from 35.66% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.50 in the past 14 days, which was higher than the 0.37 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.25, while its 200-day Moving Average is $3.13. Now, the first resistance to watch is $6.38. This is followed by the second major resistance level at $7.01. The third major resistance level sits at $7.37. If the price goes on to break the first support level at $5.39, it is likely to go to the next support level at $5.03. Assuming the price breaks the second support level, the third support level stands at $4.40.
Galectin Therapeutics Inc (NASDAQ: GALT) Key Stats
There are 64,473K outstanding shares of the company, which has a market capitalization of 370.11 million. As of now, sales total 0 K while income totals -47,050 K. Its latest quarter income was 0 K while its last quarter net income were -8,180 K.
